# Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

> **NCT05628883** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Melanoma
- Unresectable Melanoma
- Acral Melanoma
- Mucosal Melanoma
- Cutaneous Melanoma
- Ocular Melanoma
- Uveal Melanoma
- Iris Melanoma
- Conjunctival Melanoma
- Non-Cutaneous Melanoma

## Interventions

- **BIOLOGICAL:** TBio-4101
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT05628883
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-22
- **Primary completion:** 2024-12-03
- **Final completion:** 2025-03-06
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05628883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05628883, "Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05628883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*